Novavax Inc (NVAX) · Oct 29, 2026 · Other events

Novavax milestone lands as Sanofi starts flu-COVID Phase 3

$125M milestone — Phase 3 trial initiation; $125 million payment

Novavax earned a $125 million milestone after Sanofi began its Phase 3 flu-COVID combination vaccine trial, adding cash and validating the partnership pipeline.

Novavax is operating as a lean, partnership-led vaccine platform, with Sanofi handling much of Nuvaxovid’s commercial reach while Novavax monetizes its vaccine technology, Matrix-M adjuvant and development rights. Its June 30, 2026 filing already identified the flu-COVID program as a major remaining milestone opportunity and said Sanofi was expanding Nuvaxovid commercialization across additional markets.

The partnership moved from planning into a real late-stage program. Sanofi has now dosed the fifth patient in a European Phase 3 trial combining Nuvaxovid with Sanofi’s high-dose flu vaccine, which triggers a $125 million payment to Novavax. This is more meaningful than another development update: the program has crossed into the clinical stage that can support eventual regulatory filings and commercialization.

MilestoneEarned nowFuture opportunity
Phase 3 initiation payment (CLA)$125M
Manufacturing technology transfer (CLA)$75M
U.S. combination-vaccine launch (CLA)$225M

The cash is immediate, but the larger value remains conditional. The filing says Novavax is eligible for a further $75 million when manufacturing technology transfer is completed, expected in mid-2027, and another $225 million after a successful U.S. launch. Those amounts are not revenue today; they depend on manufacturing, trial, regulatory and commercial execution.

This was partly anticipated, not a surprise from nowhere. Sanofi had already signaled its intention to be an early mover in combination vaccines and was in discussions around Phase 3 timing, so the direction of travel was known. The new information is that the trial has actually started and the first major combination-product milestone has been earned. The event also adds to a partnership that Novavax says has generated more than $1 billion in revenue to date.

Bottom line: This materially advances Novavax’s partnership-led business model: it delivers $125 million now and converts Sanofi’s combination-vaccine ambition into a late-stage clinical asset. The bigger commercial payoff is still ahead and remains dependent on successful trial, regulatory and launch execution.

What to watch next

Phase 3 readout and U.S. regulatory filing

Original filing on SEC EDGAR

More Novavax Inc news

Novavax milestone lands as Sanofi starts flu-COVID Phase 3 | NVAX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.